Janus-like effects of type I interferon in autoimmune diseases.
Immunol Rev
; 248(1): 23-35, 2012 Jul.
Article
in En
| MEDLINE
| ID: mdl-22725952
In multiple sclerosis, type I interferon (IFN) is considered immune-modulatory, and recombinant forms of IFN-ß are the most prescribed treatment for this disease. This is in contrast to most other autoimmune disorders, because type I IFN contributes to the pathologies. Even within the relapsing-remitting multiple sclerosis (RRMS) population, 30-50% of MS patients are non-responsive to this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS. In this article, we discuss the recent advances in the field of autoimmunity and introduce the theory explain how type I IFNs can be pro-inflammatory in disease that is predominantly driven by a Th17 response and are therapeutic when disease is predominantly Th1.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Autoimmune Diseases
/
Interferon Type I
Limits:
Animals
/
Humans
Language:
En
Journal:
Immunol Rev
Year:
2012
Document type:
Article
Affiliation country:
United States
Country of publication:
United kingdom